Kaplan-Meier Plotter analysis revealed that lower FGL1 expression correlated with longer OS in patients undergoing anti-PD1 therapy, including those with bladder cancer, glioblastoma, and melanoma (Figure 6B). The gene discussed is FGL1; the disease is melanoma.